NOVARTIS

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public, Private

Established: 1996-01-01

Employees: 76K

Market Cap: $242.6B

Website: https://www.novartis.com/our-science/novartis-institutes-biomedical-research

Clinical Trials

Second Extension Study to Evaluate Safety and Tolerability of Influenza Vaccines in Adults and Elderly, and to Evaluate Immunogenicity and Concomitant Vaccination With Pneumococcal Vaccine in a Subgroup

Phase 3

Completed

Conditions: Influenza

Interventions: Biological: Cell culture derived seasonal trivalent influenza vaccine (cTIV)
Biological: cTIV+PV OR eTIV_a+PV
Biological: Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).
Biological: cTIV or eTIV_a

First Posted Date: 2007-12-24

Last Posted Date: 2017-01-27

Lead Sponsor: Novartis

Target Recruit Count: 1522

Registration Number: NCT00579345

Locations: 🇵🇱
4, Krakow, Poland
🇵🇱
1, Krakow, Poland
🇵🇱
3, Krakow, Poland

and more 2 locations

Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel in Patients With Acute Ankle Sprain

Phase 2

Completed

Conditions: Ankle Sprain

Interventions: Drug: Diclofenac diethylamine 2.32% gel
Drug: Placebo
Drug: Diclofenac diethylamine 2.32% gel / Placebo

First Posted Date: 2007-12-14

Last Posted Date: 2012-04-20

Lead Sponsor: Novartis

Target Recruit Count: 271

Registration Number: NCT00573768

Locations: 🇩🇪
Novartis Investigative Site, Stockach, Germany

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: vildagliptin

First Posted Date: 2007-12-13

Last Posted Date: 2012-05-02

Lead Sponsor: Novartis

Target Recruit Count: 29

Registration Number: NCT00572650

Locations: 🇩🇪
Novartis Investigator Site, Kiel, Germany

Safety and Efficacy of APL180 in Healthy Volunteers and Patients With Coronary Heart Disease (CHD)

Phase 1

Completed

Conditions: Coronary Heart Disease

Interventions: Drug: APL180
Drug: Placebo

First Posted Date: 2007-12-06

Last Posted Date: 2020-12-24

Lead Sponsor: Novartis

Target Recruit Count: 176

Registration Number: NCT00568594

Locations: 🇬🇧
Novartis Investigator Site, Harrow, United Kingdom

Safety, Tolerability and Pharmacodynamics of QAX028 Compared to Open-label Tiotropium Bromide and Placebo in Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD) Patients.

Phase 1

Completed

Conditions: COPD

Interventions: Drug: QAX028
Drug: Placebo
Drug: Tiotropium bromide

First Posted Date: 2007-12-06

Last Posted Date: 2011-04-28

Lead Sponsor: Novartis

Target Recruit Count: 29

Registration Number: NCT00568503

Locations: 🇩🇰
Novartis Investigator Site, Birkeroed, Denmark

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Phase 3

Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Drug: Placebo to Indacaterol
Drug: Salmeterol 50 μg
Drug: Indacaterol 150 μg
Drug: Placebo to Salmeterol

First Posted Date: 2007-12-05

Last Posted Date: 2011-08-18

Lead Sponsor: Novartis

Target Recruit Count: 1002

Registration Number: NCT00567996

Locations: 🇫🇷
Novartis Investgative Site, Ferolles-Attilly, France
🇮🇹
Novartis investigator site, Chieti, Italy
🇮🇹
Novartis Investigative Site, Ascoli Piceno, Italy

and more 3 locations

Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Omalizumab
Drug: Inhaled corticosteroids (ICS)
Drug: Long-acting beta 2-adrenergic agonist (LABA)
Drug: Short-acting beta 2-adrenergic agonist (SABA)

First Posted Date: 2007-12-05

Last Posted Date: 2011-06-30

Lead Sponsor: Novartis

Target Recruit Count: 116

Registration Number: NCT00567476

Locations: 🇧🇷
Novartis Investigator Site, São Paulo, Brazil

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Phase 1

Completed

Conditions: Type-2 Diabetes

Interventions: Drug: vildagliptin

First Posted Date: 2007-12-04

Last Posted Date: 2009-03-25

Lead Sponsor: Novartis

Target Recruit Count: 96

Registration Number: NCT00567047

Locations: 🇩🇪
Novartis Investigator Site, Kiel, Germany

Clinical Effectiveness of 10 cm^2 Rivastigmine Patch in Patients With Alzheimer's Disease

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine 5 and 10 cm^2 patch

First Posted Date: 2007-11-21

Last Posted Date: 2012-04-16

Lead Sponsor: Novartis

Target Recruit Count: 208

Registration Number: NCT00561392

Locations: 🇩🇪
Novartis Investigative Site, Munich, Germany

Safety, Tolerability, Immunogenicity And CPG Dosage Finding Study of Novartis CpG Adjuvanted Flu Vaccine

Phase 1

Completed

Conditions: Influenza Infection

Interventions: Biological: Adjuvanted influenza vaccine combined with CpG7909
Biological: Adjuvanted influenza vaccine combine with CpG7909
Biological: Subunit influenza vaccine
Biological: Adjuvanted influenza vaccine

First Posted Date: 2007-11-19

Last Posted Date: 2009-11-05

Lead Sponsor: Novartis

Target Recruit Count: 60

Registration Number: NCT00559975

Locations: 🇨🇭
Institute for Pharmacokinetic and Analytical Studies, Ligornetto, Switzerland

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy